{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T22:35:00Z","timestamp":1648679700409},"reference-count":106,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmologe"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1007\/s00347-013-3016-6","type":"journal-article","created":{"date-parts":[[2014,3,17]],"date-time":"2014-03-17T23:57:08Z","timestamp":1395100628000},"page":"270-282","source":"Crossref","is-referenced-by-count":1,"title":["Immunsuppressiva zur Verhinderung von Absto\u00dfungsreaktionen nach allogenen Hornhauttransplantationen"],"prefix":"10.1007","volume":"111","author":[{"given":"T.","family":"Lapp","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Maier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Birnbaum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Schlunck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Reinhard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,3,16]]},"reference":[{"key":"3016_CR1","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/S0161-6420(94)31138-9","volume":"101","author":"Maguire","year":"1994","unstructured":"Maguire MG, Stark WJ, Gottsch JD et al (1994) Risk factors for corneal graft failure and rejection in the collaborative corneal transplantation studies. Collaborative Corneal Transplantation Studies Research Group. Ophthalmology 101:1536\u20131547","journal-title":"Ophthalmology"},{"key":"3016_CR2","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/s00347-011-2348-3","volume":"108","author":"Schrage","year":"2011","unstructured":"Schrage N, Reinhard PDT, Seitz B et al (2011) Leistungsbericht der Deutschen Hornhautbanken 2009. Ophthalmologe 108:278\u2013280","journal-title":"Ophthalmologe"},{"key":"3016_CR3","doi-asserted-by":"crossref","unstructured":"Williams KA, Muehlberg SM, Lewis RF, Coster DJ (1995) How successful is corneal transplantation? A report from the Australian Corneal Graft Register. Eye (Lond Engl) 9(Pt 2):219\u2013227","DOI":"10.1038\/eye.1995.43"},{"key":"3016_CR4","first-page":"2141","volume":"27","author":"Williams","year":"1995","unstructured":"Williams KA, Muehlberg SM, Lewis RF, Coster DJ (1995) Graft survival after corneal transplantation: role of factors with the potential for recipient presensitisation. The Australian Corneal Graft Registry (ACGR). Transplant Proc 27:2141\u20132142","journal-title":"Transplant Proc"},{"key":"3016_CR5","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1055\/s-2008-1027129","volume":"225","author":"Birnbaum","year":"2008","unstructured":"Birnbaum F, Jehle T, Schwartzkopff J et al (2008) Basiliximab following penetrating risk-keratoplasty \u2013 a prospective randomized pilot study. Klin Monatsbl Augenheilkd 225:62\u201365","journal-title":"Klin Monatsbl Augenheilkd"},{"key":"3016_CR6","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1136\/bjo.2003.034017","volume":"88","author":"Mayer","year":"2004","unstructured":"Mayer K, Birnbaum F, Reinhard T et al (2004) FTY720 prolongs clear corneal allograft survival with a differential effect on different lymphocyte populations. Br J Ophthalmol 88:915\u2013919","journal-title":"Br J Ophthalmol"},{"key":"3016_CR7","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1097\/01.TP.0000158022.62059.F2","volume":"79","author":"Birnbaum","year":"2005","unstructured":"Birnbaum F, B\u00f6hringer D, Sokolovska Y et al (2005) Immunosuppression with cyclosporine A and mycophenolate mofetil after penetrating high-risk keratoplasty: a retrospective study. Transplantation 79:964\u2013968","journal-title":"Transplantation"},{"key":"3016_CR8","doi-asserted-by":"crossref","unstructured":"Birnbaum F, Mayweg S, Reis A et al (2009) Mycophenolate mofetil (MMF) following penetrating high-risk keratoplasty: long-term results of a prospective, randomised, multicentre study. Eye (Lond Engl) 23:2063\u20132070","DOI":"10.1038\/eye.2008.402"},{"key":"3016_CR9","doi-asserted-by":"crossref","unstructured":"Birnbaum F, Schwartzkopff J, Scholz C et al (2007) The new malononitrilamide immunosuppressant FK778 prolongs corneal allograft survival in the rat keratoplasty model. Eye (Lond Engl) 21:1516\u20131523","DOI":"10.1038\/sj.eye.6702727"},{"key":"3016_CR10","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/01.tp.0000191291.71003.1b","volume":"81","author":"Birnbaum","year":"2006","unstructured":"Birnbaum F, Reis A, B\u00f6hringer D et al (2006) An open prospective pilot study on the use of rapamycin after penetrating high-risk keratoplasty. Transplantation 81:767\u2013772","journal-title":"Transplantation"},{"key":"3016_CR11","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1517\/14656566.2012.673588","volume":"13","author":"Ziaei","year":"2012","unstructured":"Ziaei M, Sharif-Paghaleh E, Manzouri B (2012) Pharmacotherapy of corneal transplantation. Expert Opin Pharmacother 13:829\u2013840","journal-title":"Expert Opin Pharmacother"},{"key":"3016_CR12","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3109\/09273948.2010.486100","volume":"18","author":"Niederkorn","year":"2010","unstructured":"Niederkorn JY, Larkin DFP (2010) Immune privilege of corneal allografts. Ocul Immunol Inflamm 18:162\u2013171","journal-title":"Ocul Immunol Inflamm"},{"key":"3016_CR13","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.ophtha.2011.09.019","volume":"119","author":"Anshu","year":"2012","unstructured":"Anshu A, Price MO, Price FW Jr (2012) Risk of corneal transplant rejection significantly reduced with Descemet\u2019s membrane endothelial keratoplasty. Ophthalmology 119:536\u2013540","journal-title":"Ophthalmology"},{"key":"3016_CR14","first-page":"452","volume":"10","author":"Cunnusamy","year":"2010","unstructured":"Cunnusamy K, Chen PW, Niederkorn JY (2010) Paradigm shifts in the role of CD4+T cells in keratoplasty. Discov Med 10:452\u2013461","journal-title":"Discov Med"},{"key":"3016_CR15","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1076\/0271-3683(200004)2041-5FT322","volume":"20","author":"Slegers","year":"2000","unstructured":"Slegers TP, Rooijen N van, Rij G van, Gaag R van der (2000) Delayed graft rejection in pre-vascularised corneas after subconjunctival injection of clodronate liposomes. Curr Eye Res 20:322\u2013324","journal-title":"Curr Eye Res"},{"key":"3016_CR16","first-page":"2239","volume":"41","author":"Slegers","year":"2000","unstructured":"Slegers TP, Torres PF, Broersma L et al (2000) Effect of macrophage depletion on immune effector mechanisms during corneal allograft rejection in rats. Invest Ophthalmol Vis Sci 41:2239\u20132247","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3016_CR17","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1097\/01.TP.0000129410.89410.F2","volume":"77","author":"Slegers","year":"2004","unstructured":"Slegers TPAM, Broersma L, Rooijen N van et al (2004) Macrophages play a role in the early phase of corneal allograft rejection in rats. Transplantation 77:1641\u20131646","journal-title":"Transplantation"},{"key":"3016_CR18","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/00003226-200201000-00013","volume":"21","author":"Reinhard","year":"2002","unstructured":"Reinhard T, B\u00f6cking A, Pomjanski N, Sundmacher R (2002) Immune cells in the anterior chamber of patients with immune reactions after penetrating keratoplasty. Cornea 21:56\u201361","journal-title":"Cornea"},{"key":"3016_CR19","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1111\/j.1600-6143.2008.02285.x","volume":"8","author":"Flynn","year":"2008","unstructured":"Flynn TH, Mitchison NA, Ono SJ, Larkin DFP (2008) Aqueous humor alloreactive cell phenotypes, cytokines and chemokines in corneal allograft rejection. Am J Transplant 8:1537\u20131543","journal-title":"Am J Transplant"},{"key":"3016_CR20","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00347-007-1516-y","volume":"104","author":"Birnbaum","year":"2007","unstructured":"Birnbaum F, Reis A, Reinhard T (2007) Topical immunosuppressives after penetrating keratoplasty. Ophthalmologe 104:381\u2013387","journal-title":"Ophthalmologe"},{"key":"3016_CR21","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/00075198-200208000-00002","volume":"8","author":"Riad","year":"2002","unstructured":"Riad M, Mogos M, Thangathurai D, Lumb PD (2002) Steroids. Curr Opin Crit Care 8:281\u2013284","journal-title":"Curr Opin Crit Care"},{"key":"3016_CR22","doi-asserted-by":"crossref","unstructured":"Barrett AJ, Rezvani K, Solomon S et al (2003) New developments in allotransplant immunology. Hematol Am Soc Hematol Educ Program 350\u2013371","DOI":"10.1182\/asheducation-2003.1.350"},{"key":"3016_CR23","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/32588","volume":"392","author":"Banchereau","year":"1998","unstructured":"Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392:245\u2013252","journal-title":"Nature"},{"key":"3016_CR24","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00347-007-1517-x","volume":"104","author":"Reis","year":"2007","unstructured":"Reis A, Birnbaum F, Reinhard T (2007) Systemic immunosuppressives after penetrating keratoplasty. Ophthalmologe 104:373\u2013380","journal-title":"Ophthalmologe"},{"key":"3016_CR25","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1097\/00007890-200010270-00017","volume":"70","author":"King","year":"2000","unstructured":"King WJ, Comer RM, Hudde T et al (2000) Cytokine and chemokine expression kinetics after corneal transplantation. Transplantation 70:1225\u20131233","journal-title":"Transplantation"},{"key":"3016_CR26","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1046\/j.1365-2249.2000.01339.x","volume":"122","author":"Rayner","year":"2000","unstructured":"Rayner SA, King WJ, Comer RM et al (2000) Local bioactive tumour necrosis factor (TNF) in corneal allotransplantation. Clin Exp Immunol 122:109\u2013116","journal-title":"Clin Exp Immunol"},{"key":"3016_CR27","first-page":"1461","volume":"12","author":"Bourges","year":"2006","unstructured":"Bourges JL, Lallemand F, Agla E et al (2006) Evaluation of a topical cyclosporine A prodrug on corneal graft rejection in rats. Mol Vis 12:1461\u20131466","journal-title":"Mol Vis"},{"key":"3016_CR28","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/01.ICL.0000062460.03555.32","volume":"29","author":"Cosar","year":"2003","unstructured":"Cosar CB, Laibson PR, Cohen EJ, Rapuano CJ (2003) Topical cyclosporine in pediatric keratoplasty. Eye Contact Lens 29:103\u2013107","journal-title":"Eye Contact Lens"},{"key":"3016_CR29","unstructured":"\u201ePeri- und postoperative Behandlungsempfehlungen bei perforierender Keratoplastik\u201c der Sektion Kornea der DOG (n.d.). http:\/\/www.dog.org\/wp-content\/uploads\/2010\/02\/Behandlungsempfehlungen-Keratoplastik.pdf"},{"key":"3016_CR30","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1007\/s00109-005-0637-5","volume":"83","author":"Quinones","year":"2005","unstructured":"Quinones MP, Estrada CA, Kalkonde Y et al (2005) The complex role of the chemokine receptor CCR2 in collagen-induced arthritis: implications for therapeutic targeting of CCR2 in rheumatoid arthritis. J Mol Med 83:672\u2013681","journal-title":"J Mol Med"},{"key":"3016_CR31","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1189\/jlb.1009671","volume":"88","author":"Zhao","year":"2010","unstructured":"Zhao Q (2010) Dual targeting of CCR2 and CCR5: therapeutic potential for immunologic and cardiovascular diseases. J Leukoc Biol 88:41\u201355","journal-title":"J Leukoc Biol"},{"key":"3016_CR32","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/COH.0b013e328356e933","volume":"7","author":"Boesecke","year":"2012","unstructured":"Boesecke C, Pett SL (2012) Clinical studies with chemokine receptor-5 (CCR5)-inhibitors. Curr Opin HIV AIDS 7:456\u2013462","journal-title":"Curr Opin HIV AIDS"},{"key":"3016_CR33","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1517\/14728214.2012.673584","volume":"17","author":"Maeda","year":"2012","unstructured":"Maeda K, Das D, Nakata H, Mitsuya H (2012) CCR5 inhibitors: emergence, success, and challenges. Expert Opin Emerg Drugs 17:135\u2013145","journal-title":"Expert Opin Emerg Drugs"},{"key":"3016_CR34","doi-asserted-by":"crossref","unstructured":"Ruderman EM (2012) Overview of safety of non-biologic and biologic DMARDs. Rheumatology (Oxf Engl) 51(Suppl 6):vi37\u2013vi43","DOI":"10.1093\/rheumatology\/kes283"},{"key":"3016_CR35","doi-asserted-by":"crossref","unstructured":"Upchurch KS, Kay J (2012) Evolution of treatment for rheumatoid arthritis. Rheumatology (Oxf Engl) 51(Suppl 6):vi28\u2013vi36","DOI":"10.1093\/rheumatology\/kes278"},{"key":"3016_CR36","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.exer.2011.07.001","volume":"95","author":"Kampik","year":"2012","unstructured":"Kampik D, Ali RR, Larkin DFP (2012) Experimental gene transfer to the corneal endothelium. Exp Eye Res 95:54\u201359","journal-title":"Exp Eye Res"},{"key":"3016_CR37","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s12026-012-8293-7","volume":"53","author":"Sin","year":"2012","unstructured":"Sin W-X, Li P, Yeong JP-S, Chin K-C (2012) Activation and regulation of interferon-\u03b2 in immune responses. Immunol Res 53:25\u201340","journal-title":"Immunol Res"},{"key":"3016_CR38","doi-asserted-by":"crossref","first-page":"21965","DOI":"10.1074\/jbc.M501623200","volume":"280","author":"Kallen","year":"2005","unstructured":"Kallen J, Sedrani R, Zenke G, Wagner J (2005) Structure of human cyclophilin A in complex with the novel immunosuppressant sanglifehrin A at 1.6 A resolution. J Biol Chem 280:21965\u20132197","journal-title":"J Biol Chem"},{"key":"3016_CR39","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1002\/(SICI)1521-3773(19990816)38:16<2443::AID-ANIE2443>3.0.CO;2-B","volume":"38","author":"Martin","year":"1999","unstructured":"Martin Cabrejas LM, Rohrbach S, Wagner D et al (1999) Macrolide analogues of the novel immunosuppressant sanglifehrin: new application of the ring-closing metathesis reaction. Angew Chem Int Ed Engl 38:2443\u20132446","journal-title":"Angew Chem Int Ed Engl"},{"key":"3016_CR40","doi-asserted-by":"crossref","unstructured":"Sanglier JJ, Quesniaux V, Fehr T et al (1999) Sanglifehrins A, B, C and D, novel cyclophilin-binding compounds isolated from Streptomyces sp. A92-308110. I. Taxonomy, fermentation, isolation and biological activity. J Antibiot (Tokyo) 52:466\u2013473","DOI":"10.7164\/antibiotics.52.466"},{"key":"3016_CR41","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1002\/(SICI)1521-3773(19990816)38:16<2447::AID-ANIE2447>3.0.CO;2-O","volume":"38","author":"Nicolaou","year":"1999","unstructured":"Nicolaou KC, Xu J, Murphy F et al (1999) Total synthesis of sanglifehrin A. Angew Chem Int Ed Engl 38:2447\u20132451","journal-title":"Angew Chem Int Ed Engl"},{"key":"3016_CR42","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0008-6363(03)00533-9","volume":"61","author":"Halestrap","year":"2004","unstructured":"Halestrap AP, Clarke SJ, Javadov SA (2004) Mitochondrial permeability transition pore opening during myocardial reperfusion \u2013 a target for cardioprotection. Cardiovasc Res 61:372\u2013385","journal-title":"Cardiovasc Res"},{"key":"3016_CR43","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1146\/annurev.immunol.14.1.483","volume":"14","author":"Abraham","year":"1996","unstructured":"Abraham RT, Wiederrecht GJ (1996) Immunopharmacology of rapamycin. Annu Rev Immunol 14:483\u2013510","journal-title":"Annu Rev Immunol"},{"key":"3016_CR44","doi-asserted-by":"crossref","unstructured":"Allen A, Zheng Y, Gardner L et al (2004) The novel cyclophilin binding compound, sanglifehrin A, disassociates G1 cell cycle arrest from tolerance induction. J Immunol (Baltim Md 1950) 172:4797\u20134803","DOI":"10.4049\/jimmunol.172.8.4797"},{"key":"3016_CR45","doi-asserted-by":"crossref","unstructured":"Woltman AM, Schlagwein N, Kooij SW van der, Kooten C van (2004) The novel cyclophilin-binding drug sanglifehrin A specifically affects antigen uptake receptor expression and endocytic capacity of human dendritic cells. J Immunol (Baltim Md 1950) 172:6482\u20136489","DOI":"10.4049\/jimmunol.172.10.6482"},{"key":"3016_CR46","doi-asserted-by":"crossref","first-page":"5611","DOI":"10.4049\/jimmunol.166.9.5611","volume":"166","author":"Zhang","year":"2001","unstructured":"Zhang L-H, Liu JO (2001) Sanglifehrin A, a novel cyclophilin-binding immunosuppressant, inhibits IL-2-dependent T cell proliferation at the G1 phase of the cell cycle. J Immunol 166:5611\u20135618","journal-title":"J Immunol"},{"key":"3016_CR47","doi-asserted-by":"crossref","first-page":"7165","DOI":"10.4049\/jimmunol.166.12.7165","volume":"166","author":"Zenke","year":"2001","unstructured":"Zenke G, Strittmatter U, Fuchs S et al (2001) Sanglifehrin A, a novel cyclophilin-binding compound showing immunosuppressive activity with a new mechanism of action. J Immunol 166:7165\u20137171","journal-title":"J Immunol"},{"key":"3016_CR48","doi-asserted-by":"crossref","first-page":"43534","DOI":"10.1074\/jbc.M104257200","volume":"276","author":"Zhang","year":"2001","unstructured":"Zhang LH, Youn HD, Liu JO (2001) Inhibition of cell cycle progression by the novel cyclophilin ligand sanglifehrin A is mediated through the NFkappa B-dependent activation of p53. J Biol Chem 276:43534\u201343540","journal-title":"J Biol Chem"},{"key":"3016_CR49","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/nri1256","volume":"4","author":"Hackstein","year":"2004","unstructured":"Hackstein H, Thomson AW (2004) Dendritic cells: emerging pharmacological targets of immunosuppressive drugs. Nat Rev Immunol 4:24\u201334","journal-title":"Nat Rev Immunol"},{"key":"3016_CR50","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/nri2546","volume":"9","author":"Thomson","year":"2009","unstructured":"Thomson AW, Turnquist HR, Raimondi G (2009) Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol 9:324\u2013337","journal-title":"Nat Rev Immunol"},{"key":"3016_CR51","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/2047-1440-1-16","volume":"1","author":"Macedo","year":"2012","unstructured":"Macedo C, Turquist H, Metes D, Thomson AW (2012) Immunoregulatory properties of rapamycin-conditioned monocyte-derived dendritic cells and their role in transplantation. Transplant Res 1:16","journal-title":"Transplant Res"},{"key":"3016_CR52","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/2047-1440-1-14","volume":"1","author":"Amodio","year":"2012","unstructured":"Amodio G, Gregori S (2012) Human tolerogenic DC-10: perspectives for clinical applications. Transplant Res 1:14","journal-title":"Transplant Res"},{"key":"3016_CR53","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/2047-1440-1-15","volume":"1","author":"Obermajer","year":"2012","unstructured":"Obermajer N, Kalinski P (2012) Generation of myeloid-derived suppressor cells using prostaglandin E2. Transplant Res 1:15","journal-title":"Transplant Res"},{"key":"3016_CR54","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/2047-1440-1-17","volume":"1","author":"Riquelme","year":"2012","unstructured":"Riquelme P, Geissler EK, Hutchinson JA (2012) Alternative approaches to myeloid suppressor cell therapy in transplantation: comparing regulatory macrophages to tolerogenic DCs and MDSCs. Transplant Res 1:17","journal-title":"Transplant Res"},{"key":"3016_CR55","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/MOH.0b013e3283324f80","volume":"17","author":"Yona","year":"2010","unstructured":"Yona S, Jung S (2010) Monocytes: subsets, origins, fates and functions. Curr Opin Hematol 17:53\u201359","journal-title":"Curr Opin Hematol"},{"key":"3016_CR56","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1002\/eji.200535270","volume":"36","author":"S\u00e0nchez-Till\u00f3","year":"2006","unstructured":"S\u00e0nchez-Till\u00f3 E, Wojciechowska M, Comalada M et al (2006) Cyclophilin A is required for M-CSF-dependent macrophage proliferation. Eur J Immunol 36:2515\u20132524","journal-title":"Eur J Immunol"},{"key":"3016_CR57","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1365-3083.2006.01702.x","volume":"63","author":"H\u00e4rtel","year":"2006","unstructured":"H\u00e4rtel C, Iblher P, Puzik A et al (2006) Immunosuppressive activity of the immunophilin-binding drug Sanglifehrin A in human whole blood: potent inhibition of interleukin-6 produced by lymphocytes and monocytes. Scand J Immunol 63:26\u201334","journal-title":"Scand J Immunol"},{"key":"3016_CR58","doi-asserted-by":"crossref","unstructured":"Steinschulte C, Taner T, Thomson AW et al (2003) Cutting edge: sanglifehrin A, a novel cyclophilin-binding immunosuppressant blocks bioactive IL-12 production by human dendritic cells. J Immunol (Baltim Md 1950) 171:542\u2013546","DOI":"10.4049\/jimmunol.171.2.542"},{"key":"3016_CR59","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/j.1600-6143.2006.01729.x","volume":"7","author":"Hackstein","year":"2007","unstructured":"Hackstein H, Steinschulte C, Fiedel S et al (2007) Sanglifehrin a blocks key dendritic cell functions in vivo and promotes long-term allograft survival together with low-dose CsA. Am J Transplant 7:789\u2013798","journal-title":"Am J Transplant"},{"key":"3016_CR60","doi-asserted-by":"crossref","unstructured":"Immecke SN, Baal N, Wilhelm J et al (2011) The cyclophilin-binding agent sanglifehrin A is a dendritic cell chemokine and migration inhibitor. PLoS One 6. http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3069092\/ (Zugegriffen: 25. Juli 2013)","DOI":"10.1371\/journal.pone.0018406"},{"key":"3016_CR61","unstructured":"Schwartzkopff J, Olivares Valdez L, Bredow L et al (2011) Sanglifehrin A promotes allograft survival in rat keratoplasty. http:\/\/www.abstractsonline.com\/plan\/ViewAbstract.aspx?mID=2684&sKey=a3eec449-ac9a-44c0-a3b8-b35afc120517&cKey=5d110dad-c9dd-445f-bf0c-913e43fec86d&mKey=%7B6F224A2D-AF6A-4533-8BBB-6A8D7B26EDB3\u2009%7D"},{"key":"3016_CR62","unstructured":"Schwartzkopff J, Olivares L, Bredow L et al (2011) Hemmung von dendritischen Zellen durch Sanglifehrin A verbessert das Transplantat\u00fcberleben nach Keratoplastik. http:\/\/www.abstracts.dog.org\/abstracts\/abstract.html?id=6"},{"key":"3016_CR63","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nrd2070","volume":"5","author":"O","year":"2006","unstructured":"O\u2019Neill LAJ (2006) Targeting signal transduction as a strategy to treat inflammatory diseases. Nat Rev Drug Discov 5:549\u2013563","journal-title":"Nat Rev Drug Discov"},{"key":"3016_CR64","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/BF02740635","volume":"15","author":"Sabatini","year":"1997","unstructured":"Sabatini DM, Lai MM, Snyder SH (1997) Neural roles of immunophilins and their ligands. Mol Neurobiol 15:223\u2013239","journal-title":"Mol Neurobiol"},{"key":"3016_CR65","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0167-7799(98)01239-6","volume":"16","author":"Cardenas","year":"1998","unstructured":"Cardenas ME, Sanfridson A, Cutler NS, Heitman J (1998) Signal-transduction cascades as targets for therapeutic intervention by natural products. Trends Biotechnol 16:427\u2013433","journal-title":"Trends Biotechnol"},{"key":"3016_CR66","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1097\/ICO.0b013e3182a2c937","volume":"32","author":"Shimmura-Tomita","year":"2013","unstructured":"Shimmura-Tomita M, Shimmura S, Satake Y et al (2013) Keratoplasty postoperative treatment update. Cornea 32(Suppl 1): S60\u2013S64","journal-title":"Cornea"},{"key":"3016_CR67","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/01.ico.0000176611.88579.0a","volume":"25","author":"Perry","year":"2006","unstructured":"Perry HD, Doshi-Carnevale S, Donnenfeld ED et al (2006) Efficacy of commercially available topical cyclosporine A 0.05\u2009% in the treatment of meibomian gland dysfunction. Cornea 25:171\u2013175","journal-title":"Cornea"},{"key":"3016_CR68","doi-asserted-by":"crossref","first-page":"352","DOI":"10.3109\/09273948.2010.498657","volume":"18","author":"Utine","year":"2010","unstructured":"Utine CA, Stern M, Akpek EK (2010) Clinical review: topical ophthalmic use of cyclosporin A. Ocul Immunol Inflamm 18:352\u2013361","journal-title":"Ocul Immunol Inflamm"},{"key":"3016_CR69","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/ACI.0b013e328364d86a","volume":"13","author":"Pacharn","year":"2013","unstructured":"Pacharn P, Vichyanond P (2013) Immunomodulators for conjunctivitis. Curr Opin Allergy Clin Immunol 13:550\u2013557","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"3016_CR70","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/ICO.0b013e318199fa8c","volume":"28","author":"Birnbaum","year":"2009","unstructured":"Birnbaum F, Reis A, Reinhard T (2009) Long term use of topical tacrolimus (FK506) in high-risk penetrating keratoplasty. Cornea 28:715\u2013716 (author reply 716)","journal-title":"Cornea"},{"key":"3016_CR71","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1136\/bjophthalmol-2013-303639","volume":"97","author":"Magalhaes","year":"2013","unstructured":"Magalhaes OA, Marinho DR, Kwitko S (2013) Topical 0.03\u2009% tacrolimus preventing rejection in high-risk corneal transplantation: a cohort study. Br J Ophthalmol 97:1395\u20131398","journal-title":"Br J Ophthalmol"},{"key":"3016_CR72","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1055\/s-2002-26727","volume":"219","author":"Reinhard","year":"2002","unstructured":"Reinhard T, Reis A, Mayweg S et al (2002) Topical Fk506 in inflammatory corneal and conjunctival diseases. A pilot study. Klin Monatsbl Augenheilkd 219:125\u2013131","journal-title":"Klin Monatsbl Augenheilkd"},{"key":"3016_CR73","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s00347-009-1954-9","volume":"106","author":"Auw-H\u00e4drich","year":"2009","unstructured":"Auw-H\u00e4drich C, Reinhard T (2009) Treatment of chronic blepharokeratoconjunctivitis with local calcineurin inhibitors. Ophthalmologe 106:635\u2013638","journal-title":"Ophthalmologe"},{"key":"3016_CR74","first-page":"149","volume":"3","author":"Kari","year":"2010","unstructured":"Kari O, Saari KM (2010) Updates in the treatment of ocular allergies. J Asthma Allergy 3:149\u2013158","journal-title":"J Asthma Allergy"},{"key":"3016_CR75","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1159\/000150444","volume":"40","author":"Li","year":"2008","unstructured":"Li XQ, Buch G, Otasevic L et al (2008) Prolongation of corneal allograft survival by topical application of everolimus in experimental keratoplasty. Ophthalmic Res 40:309\u2013314","journal-title":"Ophthalmic Res"},{"key":"3016_CR76","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1007\/s00417-007-0657-7","volume":"245","author":"Birnbaum","year":"2007","unstructured":"Birnbaum F, Schwartzkopff J, Scholz C, Reinhard T (2007) Topical pimecrolimus does not prolong clear graft survival in a rat keratoplasty model. Graefes Arch Clin Exp Ophthalmol 245:1717\u20131721","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3016_CR77","doi-asserted-by":"crossref","first-page":"354","DOI":"10.3109\/09273948.2012.709575","volume":"20","author":"Zapata","year":"2012","unstructured":"Zapata G, Racca L, Tau J, Berra A (2012) Topical use of rapamycin in herpetic stromal keratitis. Ocul Immunol Inflamm 20:354\u2013359","journal-title":"Ocul Immunol Inflamm"},{"key":"3016_CR78","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1089\/108076803321637717","volume":"19","author":"Knapp","year":"2003","unstructured":"Knapp S, Bertelmann E, Hartmann C et al (2003) Intraocular availability of topically applied mycophenolate mofetil in rabbits. J Ocul Pharmacol Ther 19:181\u2013192","journal-title":"J Ocul Pharmacol Ther"},{"key":"3016_CR79","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1007\/s00347-003-0898-8","volume":"100","author":"Bertelmann","year":"2003","unstructured":"Bertelmann E, Knapp S, Rieck P et al (2003) Transcorneal-paracorneal penetration route for topical application of drugs to the eyt. Mycophenolate mofetil as a model substance. Ophthalmologe 100:696\u2013701","journal-title":"Ophthalmologe"},{"key":"3016_CR80","first-page":"52","volume":"36","author":"Pleyer","year":"1995","unstructured":"Pleyer U, Milani JK, Dukes A et al (1995) Effect of topically applied anti-CD4 monoclonal antibodies on orthotopic corneal allografts in a rat model. Invest Ophthalmol Vis Sci 36:52\u201361","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3016_CR81","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.jhep.2013.03.034","volume":"59","author":"Ha\u00efm-Boukobza","year":"2013","unstructured":"Ha\u00efm-Boukobza S, Balabanian K, Teicher E et al (2013) Blockade of CCR5 to protect the liver graft in HIV\/HCV co-infected patients. J Hepatol 59:613\u2013615","journal-title":"J Hepatol"},{"key":"3016_CR82","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1186\/1479-5876-9-S1-S9","volume":"9","author":"Gilliam","year":"2011","unstructured":"Gilliam BL, Riedel DJ, Redfield RR (2011) Clinical use of CCR5 inhibitors in HIV and beyond. J Transl Med 9(Suppl 1):S9","journal-title":"J Transl Med"},{"key":"3016_CR83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/pr.113.007724","volume":"66","author":"Bachelerie","year":"2014","unstructured":"Bachelerie F, Ben-Baruch A, Burkhardt AM et al (2014) International Union of Pharmacology. LXXXIX. Update on the extended family of chemokine receptors and Introducing a new nomenclature for atypical chemokine receptors. Pharmacol Rev 66:1\u201379","journal-title":"Pharmacol Rev"},{"key":"3016_CR84","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/S0272-6386(03)00345-7","volume":"41","author":"Hall","year":"2003","unstructured":"Hall AV, Jevnikar AM (2003) Significance of endothelial cell survival programs for renal transplantation. Am J Kidney Dis 41:1140\u20131154","journal-title":"Am J Kidney Dis"},{"key":"3016_CR85","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.cca.2012.02.009","volume":"413","author":"Romagnani","year":"2012","unstructured":"Romagnani P, Crescioli C (2012) CXCL10: a candidate biomarker in transplantation. Clin Chim Acta 413:1364\u20131373","journal-title":"Clin Chim Acta"},{"key":"3016_CR86","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/s003470050146","volume":"94","author":"Reinhard","year":"1997","unstructured":"Reinhard T, Sundmacher R, Godehardt E, Heering P (1997) Preventive systemic cyclosporin A after keratoplasty at increased risk for immune reactions as the only elevated risk factor. Ophthalmologe 94:496\u2013500","journal-title":"Ophthalmologe"},{"key":"3016_CR87","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1097\/00003226-199911000-00003","volume":"18","author":"Reinhard","year":"1999","unstructured":"Reinhard T, M\u00f6ller M, Sundmacher R (1999) Penetrating keratoplasty in patients with atopic dermatitis with and without systemic cyclosporin A. Cornea 18:645\u2013651","journal-title":"Cornea"},{"key":"3016_CR88","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1089\/jop.1996.12.425","volume":"12","author":"Benelli","year":"1996","unstructured":"Benelli U, Lepri A, Del Tacca M, Nardi M (1996) FK-506 delays corneal graft rejection in a model of corneal xenotransplantation. J Ocul Pharmacol Ther 12:425\u2013431","journal-title":"J Ocul Pharmacol Ther"},{"key":"3016_CR89","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1016\/S0161-6420(01)00759-X","volume":"108","author":"Sloper","year":"2001","unstructured":"Sloper CM, Powell RJ, Dua HS (2001) Tacrolimus (FK506) in the management of high-risk corneal and limbal grafts. Ophthalmology 108:1838\u20131844","journal-title":"Ophthalmology"},{"key":"3016_CR90","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s004170050159","volume":"236","author":"Reis","year":"1998","unstructured":"Reis A, Reinhard T, Sundmacher R et al (1998) A comparative investigation of FK506 and cyclosporin A in murine corneal transplantation. Graefes Arch Clin Exp Ophthalmol 236:785\u2013789","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3016_CR91","first-page":"985","volume":"28","author":"Brattstr\u00f6m","year":"1996","unstructured":"Brattstr\u00f6m C, Tyd\u00e9n G, S\u00e4we J et al (1996) A randomized, double-blind, placebo-controlled study to determine safety, tolerance, and preliminary pharmacokinetics of ascending single doses of orally administered sirolimus (rapamycin) in stable renal transplant recipients. Transplant Proc 28:985\u2013986","journal-title":"Transplant Proc"},{"key":"3016_CR92","first-page":"2068","volume":"27","author":"Morris","year":"1995","unstructured":"Morris RE, Huang X, Gregory CR et al (1995) Studies in experimental models of chronic rejection: use of rapamycin (sirolimus) and isoxazole derivatives (leflunomide and its analogue) for the suppression of graft vascular disease and obliterative bronchiolitis. Transplant Proc 27:2068\u20132069","journal-title":"Transplant Proc"},{"key":"3016_CR93","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/ki.1996.28","volume":"49","author":"Murgia","year":"1996","unstructured":"Murgia MG, Jordan S, Kahan BD (1996) The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients. Kidney Int 49:209\u2013216","journal-title":"Kidney Int"},{"key":"3016_CR94","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1097\/00007890-199812270-00002","volume":"66","author":"Vu","year":"1998","unstructured":"Vu MD, Qi S, Xu D et al (1998) Synergistic effects of mycophenolate mofetil and sirolimus in prevention of acute heart, pancreas, and kidney allograft rejection and in reversal of ongoing heart allograft rejection in the rat. Transplantation 66:1575\u20131580","journal-title":"Transplantation"},{"key":"3016_CR95","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ajo.2010.03.010","volume":"150","author":"Chatel","year":"2010","unstructured":"Chatel M-A, Larkin DFP (2010) Sirolimus and mycophenolate as combination prophylaxis in corneal transplant recipients at high rejection risk. Am J Ophthalmol 150:179\u2013184","journal-title":"Am J Ophthalmol"},{"key":"3016_CR96","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1007\/s00417-010-1420-z","volume":"248","author":"Stanojlovic","year":"2010","unstructured":"Stanojlovic S, Schlickeiser S, Appelt C et al (2010) Influence of combined treatment of low dose rapamycin and cyclosporin A on corneal allograft survival. Graefes Arch Clin Exp Ophthalmol 248:1447\u20131456","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3016_CR97","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1136\/bjo.83.11.1268","volume":"83","author":"Reis","year":"1999","unstructured":"Reis A, Reinhard T, Voiculescu A et al (1999) Mycophenolate mofetil versus cyclosporin A in high risk keratoplasty patients: a prospectively randomised clinical trial. Br J Ophthalmol 83:1268\u20131271","journal-title":"Br J Ophthalmol"},{"key":"3016_CR98","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/1471-2369-13-68","volume":"13","author":"Wlodarczyk","year":"2012","unstructured":"Wlodarczyk Z, Vanrenterghem Y, Kr\u00e4mer BK et al (2012) A multicenter, randomized, double-blind study comparing different FK778 doses (manitimus) with tacrolimus and steroids vs. MMF with tacrolimus and steroids in renal transplantation. BMC Nephrol 13:68","journal-title":"BMC Nephrol"},{"key":"3016_CR99","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1001\/archopht.1965.00970040685018","volume":"74","author":"Polack","year":"1965","unstructured":"Polack FM (1965) Inhibition of immune corneal graft rejection by azathioprine (imuran). Arch Ophthalmol 74:683\u2013689","journal-title":"Arch Ophthalmol"},{"key":"3016_CR100","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1007\/s00347-003-0954-4","volume":"100","author":"Pleyer","year":"2003","unstructured":"Pleyer U (2003) Immunomodulation in penetrating keratoplasty. Current status and perspectives. Ophthalmologe 100:1036\u20131044","journal-title":"Ophthalmologe"},{"key":"3016_CR101","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/PL00007114","volume":"99","author":"Schmitz","year":"2002","unstructured":"Schmitz K, Hitzer S, Behrens-Baumann W (2002) Immune suppression by combination therapy with basiliximab and cyclosporin in high risk keratoplasty. A pilot study. Ophthalmologe 99:38\u201345","journal-title":"Ophthalmologe"},{"key":"3016_CR102","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s10792-007-9100-7","volume":"28","author":"Tabbara","year":"2008","unstructured":"Tabbara KF (2008) Pharmacologic strategies in the prevention and treatment of corneal transplant rejection. Int Ophthalmol 28:223\u2013232","journal-title":"Int Ophthalmol"},{"key":"3016_CR103","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/00003226-200201000-00017","volume":"21","author":"Reis","year":"2002","unstructured":"Reis A, Megahed M, Reinhard T et al (2002) Synergism of RAD and cyclosporin A in prevention of acute rat corneal allograft rejection. Cornea 21:81\u201384","journal-title":"Cornea"},{"key":"3016_CR104","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1089\/jop.2007.0088","volume":"24","author":"Baspinar","year":"2008","unstructured":"Baspinar Y, Bertelmann E, Pleyer U et al (2008) Corneal permeation studies of everolimus microemulsion. J Ocul Pharmacol Ther 24:399\u2013402","journal-title":"J Ocul Pharmacol Ther"},{"key":"3016_CR105","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1097\/00007890-200011150-00022","volume":"70","author":"Reis","year":"2000","unstructured":"Reis A, Megahed M, Reinhard T et al (2000) Coadministration of the new macrolide immunosuppressant RAD and mycophenolate mofetil in experimental corneal transplantation. Transplantation 70:1397\u20131401","journal-title":"Transplantation"},{"key":"3016_CR106","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1111\/j.1600-6143.2012.04127.x","volume":"12","author":"Vincenti","year":"2012","unstructured":"Vincenti F, Tedesco Silva H, Busque S et al (2012) Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year. Am J Transplant 12:2446\u20132456","journal-title":"Am J Transplant"}],"container-title":["Der Ophthalmologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-013-3016-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00347-013-3016-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-013-3016-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T10:57:03Z","timestamp":1565261823000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00347-013-3016-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":106,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["3016"],"URL":"https:\/\/doi.org\/10.1007\/s00347-013-3016-6","relation":{},"ISSN":["0941-293X","1433-0423"],"issn-type":[{"value":"0941-293X","type":"print"},{"value":"1433-0423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3]]}}}